TARDBP and tauopathy: In this study, we did not assess the contribution of other neuropathologic changes such as Lewy bodies, non-NFT tauopathies, or phosphorylated TAR-DNA binding protein 43 although our clinical phenotyping of people with dementia did not reveal any participants with a clinical diagnosis of Lewy-body dementia of frontotemporal dementia.